These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11149939)

  • 1. Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival.
    Princiotta MF; Schubert U; Chen W; Bennink JR; Myung J; Crews CM; Yewdell JW
    Proc Natl Acad Sci U S A; 2001 Jan; 98(2):513-8. PubMed ID: 11149939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
    An WG; Hwang SG; Trepel JB; Blagosklonny MV
    Leukemia; 2000 Jul; 14(7):1276-83. PubMed ID: 10914553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of an inhibitor of tripeptidyl peptidase II (Ala-Ala-Phe-chloromethylketone) and its combination with an inhibitor of the chymotrypsin-like activity of the proteasome (PSI) on apoptosis, cell cycle and proteasome activity in U937 cells.
    Bury M; Młynarczuk I; Pleban E; Hoser G; Kawiak J; Wójcik C
    Folia Histochem Cytobiol; 2001; 39(2):131-2. PubMed ID: 11374791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of polyubiquitylated proteins in response to Ala-Ala-Phe-chloromethylketone is independent of the inhibition of Tripeptidyl peptidase II.
    Villasevil EM; Guil S; López-Ferreras L; Sánchez C; Del Val M; Antón LC
    Biochim Biophys Acta; 2010 Sep; 1803(9):1094-105. PubMed ID: 20553980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tripeptidyl peptidase II is dispensable for the generation of both proteasome-dependent and proteasome-independent ligands of HLA-B27 and other class I molecules.
    Marcilla M; Villasevil EM; de Castro JA
    Eur J Immunol; 2008 Mar; 38(3):631-9. PubMed ID: 18286573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A giant protease with potential to substitute for some functions of the proteasome.
    Geier E; Pfeifer G; Wilm M; Lucchiari-Hartz M; Baumeister W; Eichmann K; Niedermann G
    Science; 1999 Feb; 283(5404):978-81. PubMed ID: 9974389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells.
    Gavioli R; Frisan T; Vertuani S; Bornkamm GW; Masucci MG
    Nat Cell Biol; 2001 Mar; 3(3):283-8. PubMed ID: 11231578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The final N-terminal trimming of a subaminoterminal proline-containing HLA class I-restricted antigenic peptide in the cytosol is mediated by two peptidases.
    Lévy F; Burri L; Morel S; Peitrequin AL; Lévy N; Bachi A; Hellman U; Van den Eynde BJ; Servis C
    J Immunol; 2002 Oct; 169(8):4161-71. PubMed ID: 12370345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation.
    York IA; Bhutani N; Zendzian S; Goldberg AL; Rock KL
    J Immunol; 2006 Aug; 177(3):1434-43. PubMed ID: 16849449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Need for tripeptidyl-peptidase II in major histocompatibility complex class I viral antigen processing when proteasomes are detrimental.
    Guil S; Rodríguez-Castro M; Aguilar F; Villasevil EM; Antón LC; Del Val M
    J Biol Chem; 2006 Dec; 281(52):39925-34. PubMed ID: 17088258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope.
    Seifert U; Marañón C; Shmueli A; Desoutter JF; Wesoloski L; Janek K; Henklein P; Diescher S; Andrieu M; de la Salle H; Weinschenk T; Schild H; Laderach D; Galy A; Haas G; Kloetzel PM; Reiss Y; Hosmalin A
    Nat Immunol; 2003 Apr; 4(4):375-9. PubMed ID: 12598896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitors: valuable new tools for cell biologists.
    Lee DH; Goldberg AL
    Trends Cell Biol; 1998 Oct; 8(10):397-403. PubMed ID: 9789328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII.
    Kloetzel PM
    Nat Immunol; 2004 Jul; 5(7):661-9. PubMed ID: 15224091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity.
    Wang EW; Kessler BM; Borodovsky A; Cravatt BF; Bogyo M; Ploegh HL; Glas R
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):9990-5. PubMed ID: 10954757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells.
    Naujokat C; Sezer O; Zinke H; Leclere A; Hauptmann S; Possinger K
    Eur J Haematol; 2000 Oct; 65(4):221-36. PubMed ID: 11073163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasomes get by with lots of help from their friends.
    Yewdell JW; Princiotta MF
    Immunity; 2004 Apr; 20(4):362-3. PubMed ID: 15084265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.
    Rock KL; Gramm C; Rothstein L; Clark K; Stein R; Dick L; Hwang D; Goldberg AL
    Cell; 1994 Sep; 78(5):761-71. PubMed ID: 8087844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
    Ling YH; Liebes L; Zou Y; Perez-Soler R
    J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation.
    López D; Gil-Torregrosa BC; Bergmann C; Del Val M
    J Immunol; 2000 May; 164(10):5070-7. PubMed ID: 10799863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
    Destro F; Sforza F; Sicurella M; Marescotti D; Gallerani E; Baldisserotto A; Marastoni M; Gavioli R
    Immunology; 2011 May; 133(1):105-14. PubMed ID: 21342184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.